Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
